Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 67,700 shares, a growth of 67.6% from the November 30th total of 40,400 shares. Currently, 5.1% of the company’s shares are short sold. Based on an average trading volume of 311,300 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Price Performance

Shares of SNOA stock remained flat at $2.75 during trading hours on Friday. 39,192 shares of the company were exchanged, compared to its average volume of 208,409. The company has a market cap of $3.68 million, a price-to-earnings ratio of -0.55 and a beta of 1.43. Sonoma Pharmaceuticals has a 52-week low of $2.44 and a 52-week high of $9.37. The stock’s 50-day moving average is $2.78 and its 200-day moving average is $1.90.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.